IP Library Patent Application 18041447
Patent Application
App. No. 18/041,447

Methods of Protecting RNA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/041,447
Abstract

The present invention provides methods of protecting ribonucleic acid (RNA) from degradation under certain conditions by contacting the RNA with compounds that contain at least one boron atom. The present invention also provides compositions comprising such compounds and RNA.

Claims (96)

1 . A method of protecting RNA from degradation by contacting the RNA with a boron compound.

2 . The method according to claim 1 wherein the RNA is single strand.

3 . The method according to claim 1 wherein the RNA is antisense single strand.

4 . The method according to claim 1 wherein the RNA is messenger RNA (mRNA).

5 . The method according to claim 1 wherein the RNA encodes a viral antigen.

6 . The method according to claim 1 , wherein the boron compound is selected from the group consisting of:

N-[(5aR,6aS,7S,10aS)-9-carbamoyl-4,7-bis(dimethylamino)-1,8,10a,11-tetrahydroxy-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]-1-hydroxy-3,3-dimethyl-1,3-dihydro-2,1-benzoxaborole-6-carboxamide;

(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-9-({2-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-6-yl)amino]-2-oxoethyl}amino)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide;

N~1~-[(5R,5aR,6S,6aR,7S,10aS)-9-carbamoyl-7-(dimethylamino)-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]-N~4~-(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-6-yl)butanediamide;

(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-9-({3-[(1-hydroxy-3,4-dihydro-1H-2,5,1-benzodioxaborepin-7-yl)amino]-3-oxopropyl}amino)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide;

(4S,4aR,5S,5aR,6R,12aS)-9-({3-[(2,3-dihydro-7H-[1,2]oxaborolo[4,3,2-jk][2,5,1]benzodioxaborepin-9-yl)amino]-3-oxopropyl}amino)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide;

quinolin-8-yl {3-chloro-4-[(dimethylamino)methyl]phenyl}(3-cyanophenyl)borinate; (4-fluorophenyl){3-[(4-methylpiperazin-1-yl)methyl]phenyl}(quinolin-8-olato-kappa~2~N,O)boron;

N-[(5R,5aR,6S,6aR,7S,10aS)-9-carbamoyl-7-(dimethylamino)-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]-1-hydroxy-3,3-dimethyl-1,3dihydro-2,1-benzoxaborole-6-carboxamide;

(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-9-({3-[(1-hydroxy-3,4-dihydro-1H-2,1-benzoxaborinin-7-yl)amino]-3-oxopropyl}amino)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide;

quinolin-8-yl (3-chloro-4-cyanophenyl){3-fluoro-4-[(4-methylpiperazin-1-yl)methyl]phenyl}borinate;

N~1~-[(5RS,5aRS,6SR,6aRS,7SR,10aSR)-9-carbamoyl-7-(dimethylamino)-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]-N~4~-{[(5RS)-2-hydroxy-1,2-oxaborolan-5-yl]methyl}butanediamide;

{3-chloro-4-[(4-methylpiperazin-1-yl)methyl]phenyl}(4-cyanophenyl)(quinolin-8-olato-kappa~2~N,O)boron;

dimethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2,6-dicarboxylate;

[(3S)-4-borono-1-hydroxy-1,3-dihydro-2,1-benzoxaborol-3-yl]acetic acid;

(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-9-{[N-(1-hydroxy-3,3-dimethyl-1,3-dihydro-2,1-benzoxaborol-6-yl)glycyl]amino}-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide;

quinolin-8-yl (3-chloro-4-cyanophenyl){4-[(4-methylpiperazin-1-yl)methyl]phenyl}borinate;

quinolin-8-yl (4-cyanophenyl){3-[(4-methylpiperazin-1-yl)methyl]phenyl}borinate;

N-[(6aS,10S,10aR,11S,11aR,12R)-8-carbamoyl-10-(dimethylamino)-4,6,6a,9,11-pentahydroxy-12-methyl-5,7-dioxo-5,6a,7,10,10a,11,11a,12-octahydrotetracen-1-yl]-1-hydroxy-3,3-dimethyl-1,3-dihydro-2,1-benzoxaborole-6-carboxamide;

N-(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-6-yl)benzamide;

bis(acetato-kappaO)[1-cyclopropyl-6,7-difluoro-8-methyl-4-(oxo-kappaO)-1,4-dihydroquinoline-3-carboxylato-kappaO]boron;

N-[(6aS,10S,10aR,11S,11aR,12R)-8-carbamoyl-10-(dimethylamino)-4,6,6a,9,11-pentahydroxy-12-methyl-5,7-dioxo-5,6a,7,10,10a,11,11a,12-octahydrotetracen-1-yl]-1-hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxamide;

N-(3-{[(5aR,6aS,7S,10aS)-9-carbamoyl-4,7-bis(dimethylamino)-1,8,10a,11-tetrahydroxy-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]amino}-3-oxopropyl)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole-5-carboxamide;

quinolin-8-yl [3-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)phenyl](3-fluorophenyl)borinate;

{3-[(tert-butoxycarbonyl)amino]propyl}(trifluorido)borate(1-);

{3-[benzyl(methyl)amino]prop-1-en-2-yl}(trifluorido)borate(1-);

{(2Z)-3-(dimethylamino)-3-hydroxy-1-[4-hydroxy-2-(hydroxy-kappaO)phenyl]prop-2-en-1-onato-kappaO}(difluorido)boron;

5-phenoxy-2,1-benzoxaborol-1(3H)-ol;

bis(4-chlorophenyl)borinic acid;

(4-{[(3R)-1-(tert-butoxycarbonyl)piperidin-3-yl](3-methylpyridin-2-yl)carbamoyl}phenyl)(trifluorido)borate(1-);

N-[(3-methyl-1,2-oxazol-5-yl)methyl]-2-[(3S)-3-(2-methylphenyl)piperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine;

N-[(5R,5aR,6S,6aR,7S,10aS)-9-carbamoyl-7-(dimethylamino)-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]-1-hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxamide;

[(1Z)-1-(dimethylamino)-1-hydroxy-5-(hydroxy-kappaO)-4-phenylpenta-1,4-dien-3-onato-kappaO](difluorido)boron;

[3-(5-fluoro-2,1-benzoxaborol-1(3H)-yl)phenyl]methyl8-hydroxyquinoline-2-carboxylate;

2-({[bis(3-fluorophenyl)boranyl]oxy}carbonyl)pyridin-3-ol;

3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoicacid;

2-(4-bromophenyl)-5,6-dichloro-2H-1,3,2-benzodioxaborole;and

4,4′-{[1-(nonaboran-1-yl)-1H-borirene-2,3-diyl]bis(methylene)}diphenol, or a pharmaceutically acceptable salt thereof.

7 . A composition comprising an RNA and at least one boron compound.

8 . The composition according to claim 7 , wherein the at least one boron compound is selected from the group consisting of:

N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)benzamide;

2,2′-(cyclohexane-1,1-diyl)bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane);

5-(2-(aminomethyl)-4-(trifluoromethyl)phenoxy)benzo[c][1,2]oxaborol-1(3H)-ol;

1-hydroxy-3,3-dimethyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxylic acid;

N-(3-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-4-yl)phenyl)-5-(1-methyl-1H-benzo[d]imidazol-2-yl)pentanamide;

4-(5-(3-chlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-(1-hydroxy-2-methyl-1,2-dihydrobenzo[d][1,2,3]diazaborinin-6-yl)-2-methylbenzamide;

3-(4-fluorobenzyl)-5-(4-(((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)methyl)benzylidene)thiazolidine-2,4-dione;

4-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-((1-hydroxy-3,3-dimethyl-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)methyl)-2-methylbenzamide;

2-(6-((2-((2-aminoethyl)amino)pyrimidin-4-yl)oxy)-1-hydroxy-4-methyl-1,3-dihydrobenzo[c][1,2]oxaborol-3-yl)acetic acid;

5-phenoxybenzo[c][1,2]oxaborol-1(3H)-ol;

5-(pyridin-2-ylmethoxy)benzo[c][1,2]oxaborol-1(3H)-ol;

8-(3-aminopropoxy)benzo[d][1,2,3]diazaborinin-1(2H)-ol;

4-(aminomethyl)-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)benzenesulfonamide;

N-((1R,2R)-1-(4-((S)-3-(aminomethyl)-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)phenyl)-1,3-dihydroxypropan-2-yl)-2-chloroacetamide;

N-[(5aR,6aS,7S,10aS)-9-carbamoyl-4,7-bis(dimethylamino)-1,8,10a,11-tetrahydroxy-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]-1-hydroxy-3,3-dimethyl-1,3-dihydro-2,1-benzoxaborole-6-carboxamide;

(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-9-({2-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-6-yl)amino]-2-oxoethyl}amino)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide;

N~1~-[(5R,5aR,6S,6aR,7S,10aS)-9-carbamoyl-7-(dimethylamino)-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]-N~4~-(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-6-yl)butanediamide;

(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-9-({3-[(1-hydroxy-3,4-dihydro-1H-2,5,1-benzodioxaborepin-7-yl)amino]-3-oxopropyl}amino)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide;

(4S,4aR,5S,5aR,6R,12aS)-9-({3-[(2,3-dihydro-7H-[1,2]oxaborolo[4,3,2-jk][2,5,1]benzodioxaborepin-9-yl)amino]-3-oxopropyl}amino)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide;

quinolin-8-yl {3-chloro-4-[(dimethylamino)methyl]phenyl}(3-cyanophenyl)borinate; (4-fluorophenyl){3-[(4-methylpiperazin-1-yl)methyl]phenyl}(quinolin-8-olato-kappa~2~N,O)boron;

N-[(5R,5aR,6S,6aR,7S,10aS)-9-carbamoyl-7-(dimethylamino)-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]-1-hydroxy-3,3-dimethyl-1,3 dihydro-2,1-benzoxaborole-6-carboxamide;

(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-9-({3-[(1-hydroxy-3,4-dihydro-1H-2,1-benzoxaborinin-7-yl)amino]-3-oxopropyl}amino)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide;

quinolin-8-yl (3-chloro-4-cyanophenyl){3-fluoro-4-[(4-methylpiperazin-1-yl)methyl]phenyl}borinate;

N~1~-[(5RS,5aRS,6SR,6aRS,7SR,10aSR)-9-carbamoyl-7-(dimethylamino)-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]-N~4~-{[(5RS)-2-hydroxy-1,2-oxaborolan-5-yl]methyl}butanediamide;

{3-chloro-4-[(4-methylpiperazin-1-yl)methyl]phenyl}(4-cyanophenyl)(quinolin-8-olato-kappa~2~N,O)boron;

dimethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2,6-dicarboxylate;

[(3S)-4-borono-1-hydroxy-1,3-dihydro-2,1-benzoxaborol-3-yl]aceticacid;

(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-9-{[N-(1-hydroxy-3,3-dimethyl-1,3-dihydro-2,1-benzoxaborol-6-yl)glycyl]amino}-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide;

quinolin-8-yl (3-chloro-4-cyanophenyl){4-[(4-methylpiperazin-1-yl)methyl]phenyl}borinate;

quinolin-8-yl (4-cyanophenyl){3-[(4-methylpiperazin-1-yl)methyl]phenyl}borinate;

N-[(6aS,10S,10aR,11S,11aR,12R)-8-carbamoyl-10-(dimethylamino)-4,6,6a,9,11-pentahydroxy-12-methyl-5,7-dioxo-5,6a,7,10,10a,11,11a,12-octahydrotetracen-1-yl]-1-hydroxy-3,3-dimethyl-1,3-dihydro-2,1-benzoxaborole-6-carboxamide;

N-(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-6-yl)benzamide;

bis(acetato-kappaO)[1-cyclopropyl-6,7-difluoro-8-methyl-4-(oxo-kappaO)-1,4-dihydroquinoline-3-carboxylato-kappaO]boron;

N-[(6aS,10S,10aR,11S,11aR,12R)-8-carbamoyl-10-(dimethylamino)-4,6,6a,9,11-pentahydroxy-12-methyl-5,7-dioxo-5,6a,7,10,10a,11,11a,12-octahydrotetracen-1-yl]-1-hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxamide;

N-(3-{[(5aR,6aS,7S,10aS)-9-carbamoyl-4,7-bis(dimethylamino)-1,8,10a,11-tetrahydroxy-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]amino}-3-oxopropyl)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole-5-carboxamide;

quinolin-8-yl [3-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)phenyl](3-fluorophenyl)borinate;

{3-[(tert-butoxycarbonyl)amino]propyl}(trifluorido)borate(1-);

{3-[benzyl(methyl)amino]prop-1-en-2-yl}(trifluorido)borate(1-);

{(2Z)-3-(dimethylamino)-3-hydroxy-1-[4-hydroxy-2-(hydroxy-kappaO)phenyl]prop-2-en-1-onato-kappaO}(difluorido)boron;

5-phenoxy-2,1-benzoxaborol-1(3H)-ol;

bis(4-chlorophenyl)borinic acid;

(4-{[(3R)-1-(tert-butoxycarbonyl)piperidin-3-yl](3-methylpyridin-2-yl)carbamoyl}phenyl)(trifluorido)borate(1-);

N-[(3-methyl-1,2-oxazol-5-yl)methyl]-2-[(3S)-3-(2-methylphenyl)piperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine;

N-[(5R,5aR,6S,6aR,7S,10aS)-9-carbamoyl-7-(dimethylamino)-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl]-1-hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxamide;

[(1Z)-1-(dimethylamino)-1-hydroxy-5-(hydroxy-kappaO)-4-phenylpenta-1,4-dien-3-onato-kappaO](difluorido)boron;

[3-(5-fluoro-2,1-benzoxaborol-1(3H)-yl)phenyl]methyl 8-hydroxyquinoline-2-carboxylate;

2-({[bis(3-fluorophenyl)boranyl]oxy}carbonyl)pyridin-3-ol;

3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid;

2-(4-bromophenyl)-5,6-dichloro-2H-1,3,2-benzodioxaborole; and

4,4′-{[1-(nonaboran-1-yl)-1H-borirene-2,3-diyl]bis(methylene)}diphenol, or a pharmaceutically acceptable salt thereof.

9 . The composition according to claim 8 , wherein the RNA is messenger RNA (mRNA).

10 . The composition according to claim 9 wherein the mRNA encodes a viral antigen.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →